Tests an in-ear device that records brain waves in people with epilepsy
Tests an in-ear device recording brain waves in adults with epilepsy.
Plain-language title generated from the registry record
Registry title: SeizEAR Safety Study
Key facts
- Where
- New York, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07088835, who can take part
Where in United States
- Icahn School of Medicine at Mount SinaiNew York, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Icahn School of Medicine at Mount Sinai
- Trial code
- NCT07088835
- Record updated
- 14 September 2026
- Original description
Determine the safety and feasibility of an in-ear device to measure seizures or suspected seizures compared to the standard scalp-based electroencephalogram (EEG). The study team anticipates enrolling five healthy participants through meeting announcements and a research email list serv in the Neurology Dept. Based on the appropriate positive initial test of healthy individuals, test the in-ear device on 10 participants with seizures or suspected seizures scheduled for a clinical scalp EEG test.Read full original descriptionShow less
The Safety and Feasibility of SeizEAR, an In-ear Device to Monitor Brain Waves From Temporal Lobes and Detect Abnormalities
Determine the safety and feasibility of an in-ear device to measure seizures or suspected seizures compared to the standard scalp-based electroencephalogram (EEG). The study team anticipates enrolling five healthy participants through meeting announcements and a research email list serv in the Neurology Dept. Based on the appropriate positive initial test of healthy individuals, test the in-ear device on 10 participants with seizures or suspected seizures scheduled for a clinical scalp EEG test.
Inclusion: Age: > 18 and <70; No History of Seizures or seizure-like activity based on self-report; Normal parameters for vitals, afebrile, blood pressure; Able to read and write English; Capable of providing informed consent; Age > 18 and < 70; Individuals scheduled for clinical EEG for seizures or suspected temporal lobe seizures documented by a neurologist; Stable Health Conditions based upon the principal investigator's opinion; Normal parameters for vitals, afebrile, blood pressure; Able to read and write English; Capable of providing informed consent.
Exclusion: Concurrent participation in another investigational protocol; Treatment for an ear infection in the previous four-week period; Treatment for an ear infection in the previous four-week period; Concurrent participation in another investigational protocol; History of seizures or seizure-like activity based on self-assessment; Any major health conditions based upon self-report; A history of skin sensitivity, or rash on the head, neck or ears; A history of silver allergy; Medications that would be contraindicated to participate in the study that would interfere with the EEG Testing; Phase 3 Inclusion/Exclusion Criteria: Participants with Seizures or Suspected Temporal Lobe Seizures; A history of skin sensitivity, or rash on the head, neck or ears; A history of silver allergy; Any psychiatric disorder (i.e. uncontrolled depression, mood disorders, cognitive impairment, schizophrenia), that complicate measurement of changes associated with the EEG testing; Any major issues with the skull or ear that would interfere with the EEG testing.
Healthy Participants.